Philip Morris International Inc. (PM) Earnings Call Transcript & Summary
February 6, 2025
Earnings Call Speaker Segments
James Bushnell
executiveGood day, and thanks for being here. We put out a press release earlier today with full details about how we performed in the fourth quarter and across all of 2024. You can find that release on our site, pmi.com. Terms are explained in a glossary — that covers what we mean by smoke-free products, plus adjustments, other calculations, and reconciliations to the closest comparable U.S. GAAP measures for the non-GAAP financial measures we reference in this presentation — and all of that sits in Exhibit 99.2 of the Company's Form 8-K dated February 6, 2025, and also on our Investor Relations website. What we say today includes forward-looking statements and projections about future results. Please look at the forward-looking and cautionary statements disclosure in today's presentation and press release, which reviews the various factors that could make actual results differ materially from projections or forward-looking statements. Jacek Olczak, Chief Executive Officer, and Emmanuel Babeau, Chief Financial Officer, are with me today. Jacek, the floor is yours.
Jacek Olczak
executiveJames, thank you, and greetings to everyone. 2024 was an outstanding year for us, with each essential area of our operations contributing meaningfully to industry-leading organic growth on revenue and profit alike. As a result, we saw a substantial acceleration in adjusted diluted EPS growth, measured both in constant currency and—equally important—in actual dollars, all while absorbing sizable foreign exchange pressures. We outperformed the broader sector and consumer packaged goods overall, gaining ground in every category and delivering a fourth consecutive year of volume increases. IQOS maintained its robust underlying trajectory, posting continued outstanding gains in Japan, solid advancement in Europe even with the EU's flavor ban designation, and additional strong expansion across other markets worldwide. The key point here is that IQOS is getting more profitable as it grows, because the benefits of scale and pricing now more than offset the sizable ongoing investments in growth, such as brand-building and device and consumable innovations. In the US, ZYN delivered another strong performance, with the acceleration in demand that began in 2023 continuing throughout 2024. That led to near-term supply constraints, which we have gradually resolved across the year as we worked to keep pace with demand from existing users. With additional capacity coming online, we will be in a position to unlock the full potential of this highly dynamic category. Outside America, we shipped 75% more, taking our nicotine pouches worldwide into 37 markets. In e-vapor, VEEV keeps contributing more to our growth, with closed pods showing encouraging volume momentum and a stronger market position built on a premium offer. Every metric in our combustible business looked good; last year's Q4 brought double-digit gross profit growth, and for the full year we saw roughly 7% organic growth, fueled by solid pricing, volumes that held up in certain markets, and ongoing gains from our cost actions. All told, this strong showing across every category and region produced meaningful operating leverage, especially within our smoke-free business, alongside cost efficiency efforts reaching across the whole value chain. Even with persistent pressure from currency shifts and rising input expenses, this enabled us to produce operating cash flow and adjusted diluted earnings per share that came in higher than our initial projections for the year. There's terrific momentum behind both our transformation efforts and the factors driving growth, and we feel strongly that we can achieve lasting expansion and returns throughout 2025 and afterward. We achieved a number of significant milestones during the last twelve months as part of our smoke-free progression, among them the 10-year anniversary of IQOS and ZYN. Our smoke-free segment is substantial, generates solid profits, and is expanding rapidly. In 2024, net revenues from our smoke-free products totaled nearly $15 billion. Alongside robust results from combustibles, our organization crossed the $10 billion mark in adjusted net earnings for the very first time. During Q4, smoke-free products accounted for 40% of PMI's overall net revenues and roughly 42% of adjusted gross profit, reflecting a transformation that is now profitable in its own right. Within the five biggest markets measured by operating income, smoke-free represented about 60% of net revenues. A multi-category, smoke-free strategy now covers close to half of the 95 markets where such products are sold, and by year-end we had an estimated more than 38.5 million adult consumers across heat-not-burn, oral, and e-vapor. On the smoke-free side, volumes surpassed 1 billion cans, with nicotine pouches making up 644 million of that total. Throughout America, adult nicotine consumers continue to embrace ZYN, which remains number one in smoke-free brands and sits fourth across all nicotine brands in that market, while its international footprint keeps growing. We're equally pleased that ZYN's solid science and responsible marketing approach secured FDA acknowledgment through the recent marketing authorization spanning every U.S. ZYN variant now sold, making it the first and only nicotine pouch brand with U.S. authorization. We remain at the forefront of work aimed at expanding consumer and regulator knowledge of smoke-free products and advanced tobacco harm reduction. It is encouraging to see more governments embrace tobacco harm reduction policies that incentivize switching to reduced nicotine products rather than continued smoking, which amounts to sound public health policy. Several markets are also shifting in a favorable direction when it comes to robust regulation of nicotine pouches and e-vapor. That said, unfortunately resistance persists in many places, frequently fueled by ideology rather than facts and science, so a substantial amount of work remains ahead of us. Although hitting key milestones feels good, 10 years in, we are still only at the early stages of transforming the industry. Thanks to our strong brands along with our innovative and commercial capabilities, plenty of years of opportunity and growth lie ahead. I'm looking forward to saying more when we meet at CAGNY on February 19. At this point, I'll hand the floor over to Emmanuel, who will take everyone through the numbers and our forward view in more depth.
Emmanuel Babeau
executiveThank you, Jacek. I'll begin with the key financial results for the year. As Jacek mentioned, we saw truly exceptional growth throughout our business this year, with the swift expansion of IQOS and U.S. ZYN joined by rising contributions from VEEV and ZYN in international markets, plus significantly better combustible performance. Across our main metrics, we met or exceeded the guidance we last shared. Organic net revenue rose 9.8%, with adjusted IMS and HTU shipments, along with combustible pricing up 8.7%, all showing strength. Total shipment volume increased an excellent 2.9%, driven by ZYN and combustible volumes, landing at the upper end of what we anticipated. Along with faster cost savings, this produced organic operating income growth of 14.9% and currency-neutral adjusted diluted earnings per share growth of 15.6%, both above expectations. Our sharp emphasis on dollar-based results showed up in the 9.3% rise in adjusted diluted EPS. Consequently, we hit a record $12.2 billion in operating cash flow, well beyond both our original and latest projections, fueled by strong profit performance and beneficial working capital. Together with solid adjusted EBITDA, this let us make substantial progress on our leverage ratio, which I'll address again shortly. We finished the year on a strong note in Q4, with organic net revenue up 7.3%, even with timing and comparison challenges, particularly those tied to Red Sea disruptions, the EU Characterizing Flavor Ban for HTUs, and shipments of the ILUMA i device ahead of its launch. This came from total volume growth of 2.3%, combined with a favorable smoke-free mix and solid pricing. Along with operating leverage and manufacturing efficiencies, we achieved nearly 12% growth in organic operating income and 10% growth in currency-neutral adjusted diluted EPS; in dollar terms, adjusted operating income climbed 15%, while adjusted diluted earnings per share rose 14% to $1.55. That figure includes a favorable currency effect of $0.06, reflecting an adverse transactional impact from the previous year in Argentina, plus the shift to hyperinflationary accounting in Egypt, which also dragged down our organic growth by roughly one point on net revenues and two points on operating income. The non-cash impairment of our RBH equity investment didn't affect our adjusted financials; going forward, we might see benefits from RBH dividend income, though we're not factoring any of that into our 2025 forecast right now. Let's put 2024 into perspective against the past several years. Our organic top-line results have been reliably robust since the pandemic and picked up even more this year, as both smoke-free products and combustibles improved their momentum. Obviously, 2024 also stood out for adjusted diluted EPS growth. Our smoke-free segment's profitability sped up thanks to IQOS's operating leverage, including scale, advantageous unit economics, pricing efficiency, and the strong boost from ZYN's swift expansion at premium U.S. margins. We also gained from especially strong combustible results, and that gives crucial structural backing to the transformation we are undertaking; those trends show up even more clearly in the organic revenue and gross profit increases for the two categories during the year. Our smoke-free operation sped up to a net revenue rise of 17% and gross profit growth of 23%, climbing to nearly $10 billion in gross profit. That produced an outstanding organic gross margin gain of 330 basis points, powered by the elements I noted earlier; on the combustible side, net revenue and gross profit each rose organically by 6% and 7%, respectively, yielding 60 basis points of organic gross margin improvement. Once more our combustible unit is adding positively, since pricing and cost savings are more than offsetting a third straight year of major input cost pressures, which should moderate in 2025. I should add that adjusted gross margin for smoke-free products stood 490 basis points above combustible in Q4 and 270 basis points above for the whole year at 66.6%. Although we keep aiming at gross margin improvement in combustible, we anticipate that gap widening over time as we keep generating profitable growth from smoke-free products while putting money into new markets, brand building, and innovation. Now looking more closely at how we performed on volume, we posted a fourth straight year of shipment gains, rising 2.3% in the fourth quarter and nearly 3% for the entire year. With our VEEV e-vapor operation counted in equivalent unit, that increase came to 2.4% and 3%, respectively. Our total 2024 smoke-free volume increase, VEEV included, reached 13.5%, or 19 billion units equivalent, a faster pace than in 2023. For IQOS, we achieved HTU adjusted in-market sales growth of almost 13% and shipment volumes of 139.7 billion, both roughly matching what we had expected. Adjusted IMS growth picked up in H2 to nearly 14%, basically on target with our goal of 14% to 15%. That figure reflects vigorous growth of almost 11% in Europe, with solid momentum in the great majority of markets. As I mentioned before, Q4 HTU shipment growth carries the effect of extra shipment in the previous year to get ready for the EU characterizing flavor ban as well as the phasing impact of additional shipment to Japan in H1, largely because of Red Sea disruption. Our smoke-free business overall raised 2024 shipment volume by 24.6%, counting ZYN's U.S. gain of 51% to 581 million cans. Snus and moist snuff volumes held steady. Cigarette shipments rose 0.6%, about matching the projected increase of the international industry. Much of the cigarette market's expansion can be traced to growth in places where smoke-free products are not allowed, including Turkey, Brazil, and India. Leaving out those markets, we see a low single-digit decrease in keeping with historical patterns. Our robust full-year top-line growth of almost 10% was once again delivered via a mix of volume growth, pricing, and the favorable mix effect of the move toward smoke-free products. Pricing added 6.2%, which came from roughly 9% in combustible pricing plus 2% for smoke-free offerings. Because IQOS HTUs and ZYN each bring in more net revenue per unit, smoke-free also produced a favorable mix benefit of 1.9%. All told, smoke-free offerings accounted for 2.2% of the group's total top-line expansion across the year, which shows how ZYN acts as a real accelerator for our results. Geographic mix, as in earlier years, was a drag, mostly from combustibles, though less so thanks to strong net revenue gains in Europe. Turning to adjusted operating margins, our full-year organic improvement reached 180 basis points, and 100 basis points in dollar terms, so we met our target of growth on both measures with room to spare. That mirrors a solid Q4, when OI margin grew organically 140 basis points as gross margin gains more than offset SG&A spending. For the full year, gross margins rose organically 160 basis points and 120 basis points in dollar terms. SG&A contributed 20 basis points of margin growth, made possible by cost efficiency steps even with heavy reinvestment and commercial backing for our smoke-free business and US capabilities, particularly in H2.
Emmanuel Babeau
executiveAcross the full year, gross cost savings came in above $750 million, driven by efficiencies in how we make both smoke-free and combustible items, plus continued reductions in back-office expenses. With that, we're solidly positioned to reach the $2 billion goal we set for 2024 through 2026. Moving to smoke-free, our approximate consumer count grew by over 5 million during 2024, landing at about 38.6 million legal-age users on December the 31st. Within that number, roughly 32.2 million are IQOS users, 5.7 million are oral users, and one million are VEEV users. I'm pleased to report that IQOS user numbers rose strongly — up +3.4 million versus the previous year, and up +1.5 million in H2. This growth is wide-ranging and in step with what we've seen in recent years, even though there have been few new market launches and the EU has introduced its characterizing flavor ban. Overall, our user base grew by 1.5 million compared with the prior year, fueled by ZYN's ongoing strong momentum, as legal-age marketing carries on in the U.S. even while supply remains constrained. Turning to IQOS, the adjusted IMS volume reflects solid user momentum, posting 2024 growth above 15 billion units, which aligns with the previous year despite the E.U. flavor ban's effects. That figure also lines up with the five-year average, and it comes in more than one billion units greater once you strip out contributions from markets that launched this year or the year before. A key point is that once IQOS ILUMA launched and operations expanded, IQOS became much more profitable. The chart shown here tracks how much the product contributes using a constant return rate. We've noted previously that building a business-to-consumer setup carries heavy initial expenses, so the cost for each user drops as more users join in a given market. That pattern should keep playing out going forward. Now looking at IQOS in Europe, HTU adjusted IMS growth did speed up considerably during the second half, hitting nearly 11%, which matched expectations, after rising roughly 8% in the first half. All told, that delivered a solid 9.4% increase for the full year, even with the major upheaval caused by the characterizing flavor prohibition. In the second half, adjusted IMS rose by double digits, and that came from solid gains across many markets. Places like Bulgaria, Greece, Germany, Romania, and Spain each posted roughly 20% growth or better, whereas Poland, the Czech Republic, and Italy were not as dynamic. Italy is still recovering after the flavor ban caused disruption, though the rebound there came a bit more slowly than we had anticipated in Q4. Thanks to that ongoing momentum across the region, our adjusted share for Q4 climbed 0.9 points versus a year earlier, landing at 10.6%, while adjusted IMS volume hit 13.5 billion units on the fourth-quarter moving average. During the fourth quarter, our shipment volume rose 6% versus the same period a year earlier, a comparison that had been boosted by extra volumes tied to the flavor ban rollout, particularly in Italy. Today the flavor ban is in force across every EU market except six, and the pattern is broadly the same everywhere: a brief period of disruption, then a recovery back toward the growth path we saw before the ban. Having absorbed a reduction of about 2 billion units in 2024, we now expect roughly 1 billion units of impact in 2025, spanning shipment and IMS, including the annualization effect, and Q1 of 2025 is when that impact will be felt most. Beyond that, we're still bringing the IQOS ILUMA i device plus new consumable options like DELIA and LEVIA into additional markets, which widens the range of taste profiles and price points available to adjust the market. Over in our Key Cities in Europe, several significant milestones were hit: Budapest passed 40% share, Rome went above 30%, London is nearing 10%, and Madrid isn't far behind. Japan once again turned in exceptional results, posting HTU adjusted IMS growth of nearly plus 13% for the quarter and for the full year, landing at an adjusted Q4 share of 30.6%, which is + 3.1 points above the prior year. Fueling this were continued share increases for TEREA and SENTIA, alongside strong traction for the IQOS ILUMA i, with our adult user base now exceeding 9.5 million. Across the whole heat-not-burn segment in Tokyo, December offtake share reached 52.8%, and adding Shizuoka plus Hamamatsu brings the total to 10 cities and five prefectures that have crossed the 50% share mark. On a national offtake basis, smoke-free products make up 47% of the overall industry. Outside Europe and Japan, adjusted in-market sales growth maintained its robust Q4 pace. Promising broader expansion is reflected in HTU shares across Saudi Arabia, Indonesia, and Mexico. Innovation that keeps going is a big driver of this expansion. In Indonesia, clove versions of TEREA and the capsule gave the quarter a boost, and we're also seeing some promising early signals from the BONDS trial, which is our entry-level product. Over in Korea, IQOS continues to do well, although offtake share took a hit from developments in the combustible segment, where rival supply came back to usual levels and the previous quarter had been unusually strong in the wake of the IQOS ILUMA launch. Our HTU offtake share in duty-free improved nicely as we start to draw on the advantages of our multi-category lineup to push combined sales of IQOS, ZYN, and VEEV. Turning now to the U.S. Turning to our IQOS ILUMA i launch, the first campaign—running in Austin—is moving along nicely, and we expect to begin selling devices and HTUs directly there near the end of Q1. Adult smokers have shown strong interest: over 4,000 have joined our waitlist. Drawing on lessons from this early consumer engagement, we intend to launch pilots in other cities. As in Austin, our approach will center on targeted engagement with adult consumers and on raising awareness through category and brand education in communities of legal-age smokers. We are not factoring in any significant volume from U.S. IQOS before the full-scale rollout of IQOS ILUMA, and we continue to hope for FDA authorization in the second half of 2025. Shifting to ZYN now, where sustained demand drove Q4 U.S. shipment volume growth of +42% year-on-year, reaching 165 million cans. Even with the production constraints we're still facing, this shows things speeding up to a sequential gain of + 16 million cans over Q3, which is close to a record. Looking at the whole year, our shipment volumes rose by + 196 million cans compared with 2023, which underscores how big the growth was and how much effort went into getting the most out of our production capacity. ZYN's category share kept improving step by step across the second half, hitting 65.9% in Q4 as we made further progress on raising production and backed the category's growth. In fact, as this chart shows, category growth decelerated sharply during the summer, which was the peak of our supply constraint. Once things began to steadily get better, ZYN was once again driving and exceeding the category. I'm happy to report that underlying demand from adult consumers for ZYN kept rising in Q4 and came in above what we had assumed earlier. We're still seeing some out-of-stock situations at retail, and although production capacity keeps growing, our target now is full normalization at some point in the second half of 2025. We're still aiming for roughly 900 million cans of capacity for the entire year out of our Kentucky facility, and as supply keeps getting better, we'll seek to grow further beyond our current consumer base into other legal-age marketing users.
Emmanuel Babeau
executiveOur Colorado greenfield facility should start operations at the beginning of 2026, and we feel we're in a strong position to realize ZYN's potential across the years ahead. Sensible oversight of this sector is essential to enabling lasting expansion for such a vibrant category. So we're pleased about the FDA's recent clearance for the marketing and sale of every ZYN nicotine pouch now sold in the U.S., which came after the agency conducted a thorough scientific assessment. As noted earlier, that makes ZYN the first and only nicotine pouch with authorization on the market. Factors taken into account included the considerably reduced level of harmful constituents compared with cigarettes and other smokeless tobacco products, plus today's low usage rates. By acknowledging the part ZYN can play in offering legal-age adults better alternatives to cigarettes and other traditional tobacco products, the FDA's authorization represents a significant move in protecting public health; we stay dedicated to advancing industry standards in under-21 prevention, through policies and initiatives crafted to help stop youth access. Additionally, fighting the trade in illicit tobacco and nicotine products continues to be a central priority, and we commit a substantial amount of resources in support of that work. Beyond the U.S., ZYN has a promising future as well. Although it's still at a very early stage, international nicotine pouch shipments rose by 27 million cans, or +75%, and we're already seeing solid volume momentum in major international markets including Pakistan, South Africa, Mexico, the U.K., and global duty-free; during the quarter we introduced nicotine pouches in six additional markets, bringing the worldwide total to 37, among them Italy, Romania, and Thailand. Turning to e-vapor, we keep seeing robust consumer traction for VEEV ONE, the brand's overall top three post-launch position across 13 European markets, while holding the number one spot in five, Italy included. Within our multi-category strategy, VEEV serves a key role as a progressively trusted option for smoke-free category poly users and a driver of incremental growth with improving economics. For the combustible business, our main focus is maximizing value over time while backing the growth of the smoke-free business. Pricing and cost efficiencies are the primary levers for driving performance while we maintain our category leadership. We posted another strong volume quarter, with growth of 1.1%. Every region contributed to robust Q4 organic net revenue growth of +6.2%, and gross profit climbed by +10.8%. Full-year pricing of +8.7% reflects strong contributions from Germany, Egypt, and Turkey. We anticipate organic 2025 combustible pricing normalizing to +5% to +6%, partly reflecting Egypt's shift to hyperinflationary accounting in Q4 2024. Category share was flat in Q4, as positive contributions from Turkey and India were offset by decline in Egypt and Indonesia, alongside continued growth in the below-Tier 1 segment. For the full year, we grew category share +0.1 points, hitting an all-time high for both Marlboro and our global brands overall. Turning to what we see ahead for 2025, it should be one more year of robust expansion across every category, fueling delivery on both the top and bottom lines. We're looking at positive volumes for a fifth year in a row, rising by as much as +2%, led in particular by yet another year of sizable gains in smoke-free products, somewhere around +12% to +14%. With IQOS, we anticipate momentum staying strong, and the absolute increase in HTU adjusted IMS volume should land at a level similar to 2024, which works out to +10% to +12% growth. Shipment growth ought to track broadly with that double-digit path, though shipment timing and trade inventory movement carry their usual inherent volatility. Within the U.S. nicotine pouch category, we see the strong growth dynamic continuing. Even with the supply constraints I noted earlier, our forecast for U.S. ZYN volume shipments sits at a range of 780 million — 820 million cans for the year, backed by capacity expansion. That marks one more year of structural acceleration in volumes, with an expected rise of approximately 200million- 240 million cans versus the 196 million can increase in 2024. On that basis, total PMI organic net revenue growth is forecast at + 6% to + 8%. That figure absorbs a headwind exceeding 100 basis points from hyperinflationary accounting in Egypt plus the technical effect of rolling out a new commercial model in the Indonesia below-Tier 1 segment. The Indonesia change carries no impact on operating income. Further down the P&L, ongoing smoke-free mix effect, operating leverage, and cost efficiency should push adjusted operating growth into double digits at + 10.5% to + 12.5%. Gross profit growth is included there and is strong, and both gross and adjusted operating margin are forecast to expand in organic and adjusted dollar terms at prevailing exchange rates. On an organic basis, SG&A costs should rise broadly in line with net revenue as we put investment behind our smoke-free products; currency-neutral adjusted diluted EPS growth is forecast at +10.5% to +12.5%. Essentially stable net interest expense is factored in, along with a rise in our effective corporate tax rate to approximately 22.5%-23.5% stemming from tax increases consistent with OECD Pillar Two global minimum tax and the mix of international earnings; measured in dollars, we forecast growth of +7% to +9%, reaching a range of $7.40-$7.70. An unfavorable forecast currency impact of $0.22 at prevailing exchange rate is included, mainly from the dollar's growth strength, mitigated by our hedging activity. For Q1 of 2025, we expect a strong start to the year, with net revenue and operating income growth broadly in line with our full-year objective despite the leap year comparison. HTU adjusted IMS growth is forecast at around +10%, which takes into account the large annualization impact from the EU flavor ban in the quarter, with progressive improvement as the year goes on. For HTUs, shipment volume is forecast at 35 billion-36 billion, and for U.S. ZYN at 170 million-180 million cans. For Q1, our Adjusted Diluted EPS guidance sits at $1.58-$1.63. That figure bakes in a $0.04 hit from currency at prevailing rates, plus an effective corporate tax rate that runs 2 to 3 points above what we saw in the same quarter last year. Given how 2024 is landing and what we see for 2025, we're in a strong spot to hit or beat every metric in the 2024 to 2026 targets we laid out at our 2023 investor day. That holds particularly for operating income growth and for EPS delivery, since the algorithm behind those targets assumed corporate tax rates staying flat at 2023 levels. Growth of this kind on both the top and bottom lines amounts to a best-in-class profile among large-cap consumer packaged goods companies. Just as important, we remain firmly on track to turn in high single-digit adjusted diluted EPS growth in dollar terms over the 2024 to 2026 stretch at prevailing exchange rates. Our cash flows, after all, get measured in dollar, and following a record 2024, we're looking at roughly $11 billion of operating cash flow for 2025. That's more or less level with 2024 once you factor in two non-recurring payments totaling about $1 billion. We're still appealing the German tax surcharge case, but we've chosen to make a $0.8 billion payment this year, and we also expect the final transition tax payment tied to the U.S. Tax Cuts and Jobs Act.
Emmanuel Babeau
executiveWe're looking at roughly $1.5 billion in capital spending, and a big chunk of that ties to ZYN, since we're putting investment priority behind our smoke-free products. Thanks to our robust 2024 cash flow and EBITDA growth, plus a helpful effect from hedging on our Euro balance sheet, we managed to bring our net debt-to-adjusted EBITDA ratio down by 0.5x to 2.66, which came in ahead of what we expected and amounts to a dramatic acceleration of our delivery agenda. We're anticipating more progress in 2025, which keeps us on track for a target ratio of around two times by the end of 2026. Now I'll hand it back to Jacek for concluding remarks.
Jacek Olczak
executiveAppreciate that, Emmanuel. To wrap up, 2024 proved an outstanding year for PMI. The numbers we posted reflected just how powerful our strategy is and how well our transformation has gone, driven by underlying momentum across categories and supported by the steps we took proactively on pricing and cost efficiency. I have every confidence in where we stand as the global smoke-free champion as we keep executing our multi-category strategy with leading premium brands: IQOS, ZYN, and VEEV. Looking at 2025, our key strategic priorities are clear as we keep backing the expansion and development of our smoke-free business both in the U.S. and internationally. We anticipate continued strong momentum in 2025, and we have every confidence in our ability to deliver or exceed our 2024 to 2026 growth targets as we move toward our ambition of becoming substantially smoke-free by 2030. Last, and importantly, our strong growth output and highly cash-generative business lets us keep reinvesting in our smoke-free transformation while returning cash to shareholders. In September, we raised our annual dividend for the 17th consecutive year, consistent with our long-term commitment. Thank you, and Emmanuel and I will be heading out to answer your questions.
Matthew Smith
executiveHi, Jacek and Emmanuel.
Emmanuel Babeau
executiveGood morning, Matt. Good morning.
Matthew Smith
executiveFor 2025, our guidance has HTU shipments, whether measured in units or by in-market sales growth, coming in pretty close to the 2024 performance. That said, can you walk us through what makes up that growth? If the total is roughly the same, are different regions contributing differently under your outlook? Also, could you refresh us on whether new markets are adding anything to growth in 2025, or whether you've gained any ground in those markets as you look ahead to your 2026 objectives?
Jacek Olczak
executiveThanks. So with the guidance, we're basically still looking at solid expansion across Japan and several European markets. Emmanuel brought up Italy, Czechia, and Poland — places where growth is running a bit under what we'd anticipate at this point, particularly Italy and Czechia after the flavor ban. That said, we're starting to see some rebound, so ideally in the back half of the year we can get Italy and the other geographies in that group up to where the rest of Europe stands. And no meaningful new market opening has been factored into the guidance when it comes to volume. As you're aware, and as I noted in my remarks, we're contending with this rational world, battling the irrational one. My hope is that FDA's recent clearances — first for heat-not-burn, and now for pouches — will serve as a solid incentive or nudge for other governments that, frankly, foolishly stand against smoke-free products while still permitting cigarettes. But in the guidance, we haven't included any substantial volume from new geographies. So it's entirely organic growth, and as the quarters this year show, even in Japan, where close to half the market has already converted to smoke-free products, that growth keeps going.
Matthew Smith
executiveThank you, Jacek. I'll pass it on.
Bonnie Herzog
analystAll right. Thank you. Hi, Emmanuel and Jacek.
Jacek Olczak
executiveGood morning Bonnie.
Bonnie Herzog
analystI wanted to ask about your margins. You're projecting strong operating leverage on a currency-neutral basis for this year. So I was hoping you could point out some of the main factors driving that; and also, I kind of wanted to check whether your guidance bakes in a possible U.S. launch of ILUMA, or whether it's just perhaps ongoing investments with no sales to match. Then how should we think about what ZYN contributes to margins in the U.S; and how long could it take once you've entered this market for those margins to become truly meaningful?
Jacek Olczak
executiveAlright, Bonnie, good morning — let me jump in there. So yes, we are aiming for strong margin growth this year. It may not land at exactly the same level we saw last year, but I'd still call it robust, somewhere in the neighborhood of 100 basis points; that's the range we're examining. Several elements combine to drive this. Pricing contributions remain a factor, which goes without saying. Positive mix clearly plays a role too, across the categories, and particularly now that our smoke-free category is on a favorable margin trajectory, e-vapor included. So we're quite pleased that our approach of moving selectively, yet with the proper effects in the geographies where it matters, means we aren't really forsaking money, so to speak, forsaking margin. So that will add its part. In earlier periods, as you'll recall, FX created considerable headwinds, and my sense is those are now behind us, alright? And of course, there's plenty of talk going around these days, particularly out of the U.S., regarding tariffs and similar matters; however, given how we've structured our supply chain, as you're aware, the U.S. for ZYN is basically self-sufficient. As for our supply chains in Europe — well, we've arranged them largely by blocks, so at this point I don't anticipate any shocks arising on the tariff front. So I'd say we feel fairly confident about where we end up with COGS this year. There's clearly continued support derived from IQOS scale, devices in particular. And sure, economies of scale exist, and the device's robustness in quality terms and so forth. So unlike earlier times, we don't really face that bit of margin pressure stemming from device sales. So we've got that nicely stabilized for 2024. That sat behind the margin expansion. And my expectation is the same, or rather we anticipate the same, for 2025. Now, regarding your questions about ILUMA margins in the US, alright, perhaps let's take them one at a time. We continue to hope we'll receive authorization for IQOS ILUMA near the midpoint of this year. Once more, on one hand, a person might interpret this as a positive sign that following, as we mentioned, that rigorous scientific review and so forth, FDA has granted authorizations covering every variant of ZYN. It wouldn't be like me to skip saying that, clearly, when something stretches across 5 years, there has to be a good reason, since I otherwise can't account for why it would take so long. Still, my hope is that the FDA picks up the pace, and IQOS ILUMA has already been sitting in the queue for some time, and incidentally, you also have the authorization for ZYN. So on the margin story, I'll say again what I've said before: clearly, once we begin putting support behind ILUMA, meaning in that early stretch, it's going to drag things down, correct? But in the grand scheme, and given the P&L scale, if you will, of what we do in the U.S., my sense is this shouldn't be cause for much concern. My view is the U.S. will follow a comparable trajectory to the one we saw with heat-not-burn elsewhere; within 2 to 3 years, IQOS ought to contribute positively on a net basis to the bottom line. Keeping in mind, as ever, a reminder for everyone that cannibalization really isn't a headwind we face, correct? Truly, we don't; our starting position is stronger. Our confidence in IQOS ILUMA abroad keeps building, yet we're aware of what IQOS ILUMA delivered for us abroad across the past 3 years, and it keeps driving growth along with user acquisition. To my mind, it genuinely is a strong proposition for adult smokers located in the U.S.
Emmanuel Babeau
executiveTo add on the margin front, Bonnie, as you can tell from the guidance we've given, we hold considerable ambition when it comes to improving margin in 2025. The reason behind that is we're running on multiple engines for margin improvement, and all of them are aligning favorably at the same moment. So yes, naturally, there's the mix evolution working strongly in our favor, since smoke-free products carry a higher margin, and they're expanding at a very rapid pace. Within that smoke-free lineup, we have the U.S. and ZYN, which is expanding at an even quicker rate and which, as we've already mentioned, ranks best in class when it comes to margin. So that's clearly a benefit. We're also raising price. Sure, obviously, we won't keep delivering 8%+ price increase on combustibles, but it will stay extremely robust. And we likewise hold the ambition to grow our price, not to the same degree, but substantially across our smoke-free portfolio; and then when we turn to our COGS, we're focused on productivity; those carry scale effect that are contributing favorably. And as you're aware, we had been up against, until now, a significant headwind on cost, particularly in the combustible business. That is easing. 2025 should be better, and 2026 could be even better than 2025, incidentally. So we're heading in the right direction there, and that is leading us to clearly target nice margin improvement, both organically and in dollar terms for 2025.
Bonnie Herzog
analystAll right, that's really useful. And I'll jump in with a quick follow-up, since you sort of addressed it already, though earlier today you brought up aiming—or rather, still aiming—for combustible gross margin growth. Then you noted that you anticipate the spread widening compared with the gross margin on your smoke-free offerings. In the past, you folks referenced what I believe was a gap of 10 points. So as combustible gross margins rise, my take on what you're saying is that this isn't only an opportunity, but also that smoke-free margins will keep expanding, which you just brought up; so do you see that spread getting bigger? I mean, does it reach a 15-point difference, or might it hit 20? I'm just sort of attempting to work that out over the coming couple of years.
Emmanuel Babeau
executiveLook, regarding the consumable, we've already pointed out that a gap of 10 percentage points existed, and over the past few years it has been widening; so yes, we hold the ambition to improve gross margin on combustibles, and we've explained the reasons; but since we keep advancing quickly on smoke-free products as well, both through the mix effect from ZYN and, separately, on IQOS and ZYN, we intend to keep making progress. So indeed, a gap between smoke-free products and combustibles could keep widening in the years ahead.
Bonnie Herzog
analystAll right. Thank you. I'll pass it on.
Emmanuel Babeau
executiveThank you. Thank you, Bonnie.
Gaurav Jain
analystMorning, Emmanuel and Jacek — appreciate you taking my questions. I've got two things I'd like to ask. First, regarding ZYN: when I check the scan data, your volumes have slowed down to growth in the mid-teens, while your guidance calls for growth of 34%-41%. On top of that, you noted that supply normalization wouldn't occur until 2H 2025. So what I'd really like to grasp is this — what's behind the confidence that ZYN will all at once speed back up to that growth rate of nearly 40%?
Jacek Olczak
executiveAll right, and good morning to everyone. So we’re also examining how shipment and sales volumes moved during Q4, or across the weeks making up that final quarter. What we observe is strengthening velocities for ZYN. In fact, as far as I can tell, it stood out as the sole brand during those recent weeks posting gains in velocity — the remaining ones, or at minimum the four other large brands, plus the smaller yet still sizable ones, did not. Look, we must also keep in mind that we are interpreting all of this information without a complete supply picture, given the constrained supply situation, correct? That makes it somewhat tricky to draw conclusions from what shows up at retail. It even varies depending on which source you consult, and it can differ considerably from what we actually ship into the trade. Yet during Q4, exactly as we anticipated thanks to added capacity at Owensboro, we recorded our first quarter delivering meaningful sequential growth from one quarter to the next. Even if you were to extrapolate from the run rate observed in recent weeks and so on, I’d say the guidance more or less captures what we’re seeing. Turning to our remarks that we expect to satisfy demand around the middle of this year — I need to add one caveat: it’s genuinely hard to get a clear read on demand, since we understand the extent of out-of-stocks. We understand what current ZYN users want from the product, while recognizing that these purchases, or buying activity, is to some degree shaped by the unfortunate reality that they run into unavailable product, out of stock. Then there’s all the favorable momentum behind ZYN. I’d point as well to the FDA authorizations, which on one hand might be seen as merely confirming a product already on the market — so nothing changes. In truth, I think it delivers considerable visibility and stability for every participant in the market, the trade included. I’d say the same for consumers: the product now holds what I’d call full-fledged authorization across every flavor variant. So all of this, in my view, will feed into volumes — our volume projections — and that will be reflected in our guidance.
Gaurav Jain
analystAlright, let me ask something that builds on that. With ZYN obviously facing a shortage of supply, stores have been adding their own margins. From what I recall, you raised prices by $0.30 in the prior year, whereas retail pricing went up by $1, or between $3 and $5. What's your approach to managing the price at retail? And once supply returns to normal, could you bring retail pricing back down, which would then help your volumes too?
Jacek Olczak
executiveRight. So when you've got the kind of shortage that ZYN is going through, managing pricing over at the retail level clearly becomes a bit tougher, isn't that so? I mean, that's fairly evident. Yet my view is that as demand keeps expanding — pardon me — as the supply of the product keeps expanding, I think this pricing is going to reach some kind of natural normalization. So I should likewise acknowledge that, look, we're extremely pleased with the backing we receive from retailers who carry our products. And it isn't so simple for them either to be up against a product that, on one hand, has the demand, while on the other hand, they're unable to achieve their margins and they take from a ZYN price; and I'm hopeful, but once more, I think that these pricing circumstances in the market will work themselves out in some natural manner at the point when the product is available in a more fully unconstrained supply. As we've stated, in the second half of 2025, we ought to begin witnessing improvement on this.
Gaurav Jain
analystAlright. If I may fit in a final question regarding ZYN Ultra, might you discuss that PMTA, describe what this product consists of, and tell us when you expect it will become available on the market?
Jacek Olczak
executiveYes. So, clearly, as everyone saw, the ZYN approval arrived basically during the final days, or even hours, of one administration. At this point, I suppose we must wait and see what the new administration does. As I mentioned when responding to earlier questions, I genuinely hope that a stretch of four or five years spent waiting for authorization is excessive. It takes far too long. I also truly think there will be some speedups in how these are handled, I hope, thanks to the authorizations; and we should recognize too that part of the difficulty the U.S. market faces with the e-vapor product stems from the fact that the legal side of the market hasn't been established. On one hand, FDA is doing many correct things when it comes to law enforcement and pursuing the illegal Chinese or other imports; yet on the other hand, smokers and adult nicotine users do have demand for this kind of product. And if we don't build the legal side of that market quickly, then essentially we are squandering our time and money. So I do think FDA will factor this in as well — that this kind of situation ought not to occur in our product categories. And where there is demand for a product to be acknowledged as a superior alternative to cigarettes, we likewise have an interest in establishing the legal side of the market and then handling law enforcement, etc., against the illicit market. But you simply cannot police the illicit market alone if you haven't made legal solutions available in the market. So I do think that IQOS, sorry, IQOS too, but ZYN has certain pending authorizations, or applications, rather. And I do think those will be handled more quickly than was the case previously.
Gaurav Jain
analystThank you so much.
Emmanuel Babeau
executiveThank you, Gaurav.
Eric Serotta
analystGreat. Thanks, guys.
Jacek Olczak
executiveGood morning, Eric.
Eric Serotta
analystI'd appreciate it if you could shed some light on what's happening over in Italy. You said Q4 came in somewhat weaker than you'd been expecting, following that solid bounce-back during Q3 after the characterizing flavor ban; regarding Poland, could you remind us of the timing you're anticipating for disruption stemming from the ban taking effect, and what kind of effect you foresee for the overall European combustibles business? Then finally, on FX, the FX headwind you flagged for the year within the guidance appears somewhat smaller than what spot rates and your usual yen hedge would seem to suggest. I'm curious whether the hedging policy has shifted at all, or whether there's some reason it might come in a bit below what was expected. Thank you.
Jacek Olczak
executiveRight. So I'd say the final item is the simplest, and then I'll return to Italy, which has a somewhat longer story. I mean, at spot rates, we're at $0.22 right now, and honestly, the Russian ruble is the largest driver of the negative, and that's well over 60% of the variance. The yen actually moves in a cent. I believe, if I remember correctly, it was roughly $0.04 in our estimates at spot rates. Naturally, as everyone knows, these are pretty dynamic times at this moment, but that's how it is. A big contribution last year came from the Egyptian pound, correct? I mean, we had to absorb that, and obviously it won't happen again in 2025, and in fact, this will lead to a positive currency variance. But that's regarding currency, so honestly, at this point, it's the ruble. Like I said, around $0.04 on the yen, and everything else is simply a mixed bag because of our international footprint. Emmanuel would like to add something.
Emmanuel Babeau
executiveActually, let me tack on a point, since I believe the currency-market swings we're witnessing right now are arguably a decent vote of confidence in how our setup is performing. First, though, keep in mind that our balance sheet carries a substantial built-in hedge, since over 60% of what we owe is denominated in euro. As a result, whenever the euro softens against the dollar — something we've observed lately — we naturally take a hit on our P&L, yet at the same time our dollar-denominated obligations shrink. On top of that, we gain from a cheaper cost on that euro debt, and naturally from reduced interest expense in euro once converted into dollar. That has clearly supported our path through 2024, and should the euro keep weakening, it would keep working in our favor going forward. What the market likely isn't fully pricing in is that we additionally hold two sizable hedge positions: the first covers our yen exposure for 2025, with roughly 60% of that exposure hedged at approximately 138 JPY per dollar — meaning any possible slide in the JPY won't touch that portion. The second is a smaller hedge — excuse me, a lower hedge — on euro, covering a bit more than one-fifth — sorry, one-fourth — of our euro exposure at one-twelve, which likewise somewhat caps the P&L hit when the euro declines. So, taken together with what I've said, and with what Jacek has shared regarding today's Forex impact on us, you now have the full picture.
Jacek Olczak
executiveRight. So regarding Italy — I'd say yes, the latter six months came in somewhat softer than we might have anticipated. Italy, you know, was following along like plenty of other EU member states, not every one of them, but a good number, when it came to that flavor prohibition. What we're observing, I think, is this: certain smokers, certain users, held out some temporary optimism by going back to cigarettes, and that danger was always there. That also sheds light on why cigarette performance in certain markets looks a touch stronger than you'd otherwise predict or assume. There's a fair amount of dual usage involving e-vapor items; and that, in my view, might partly clarify why our VEEV offering moved ahead furthest in Italy, correct? And this occurred with a VEEV, within pods, within a closed system, and quite soon, after only a brief stretch, it climbed or shifted into the leading offering. So I think we ought to perhaps examine the smoke-free category across a stretch of time on an aggregate basis, since some dual usage will exist and is at times prompted by occurrences such as this one, by this flavor prohibition; yet we likewise have European markets where, very soon following the flavors ban taking effect, I mean, they genuinely went back to the expansion rates we'd seen previously. So perhaps Italy stands as an exception. We're examining this entire matter. But as I mentioned, one element of our multi-category approach is also that, if any leakage should occur among heat-not-burn consumers, we're able to seize that with our offering; and after that, I suppose we require somewhat more time to observe the stabilization. Poland — you brought up Poland. My sense is Poland hasn't planted the flag on the exact date they truly intend to carry out the ban completely. So I believe it will occur, I believe, at some point during 2025, but it must be — if the flag hasn't been planted, then it leans more toward the latter part of this year.
Eric Serotta
analystGreat. Thanks so much.
Emmanuel Babeau
executiveThank you.
Jacek Olczak
executiveThank you.
Faham Baig
analystMorning, everyone. Thanks for taking the questions. Hi, folks. I've got a couple as well, and the first one is about ZYN in the US again; we saw that a few of your competitors have rolled out synthetic moist nicotine offerings. And based on scanner data, there's been some early adoption. What's your read on how moist and dry will play out in the U.S.? And where do you expect the consumer to land down the road, given that in Europe the majority of products are moist? Then the second one ties back to what you said about Italy; but over a longer horizon, we see the vapor category still expanding pretty robustly. And we can talk about its shortcomings regarding flavors, marketing, underage use, and so on. But do you view that as a headwind for the tobacco industry? Or do you think the overall pie can keep expanding with only a limited effect on tobacco?
Jacek Olczak
executiveYeah. So on the second part, I'd say the overall pie does expand even though, within smoke-free, there's movement between the categories, and there's some dynamics, right, among heat-not-burn, e-vapor, and now pouches, depending on how a given market is structured and regulated. We also recognize that the hardest category to actually read, because of how the market is currently structured, is e-vapor, right? Since you've got disposables, pods, and still open tank systems, and certain products sit under the regulations and are properly authorized depending on the jurisdiction. Other products simply appear on the market; so you could describe those as various forms of illicit trade. But I think you're seeing this in the U.S., and also in Europe, in the U.K., and a handful of other places, where regulators and governments are taking a more serious look at properly organizing that market. I can't say whether that will be finished in 2025, but without a doubt there are movements, and the moves are heading in the right direction. So my belief is that in 2025, 2026, the category should be normalized through the fact that it will be properly regulated. And then we go from there. I don't want to get into youth exposure and so on, because, obviously, you know our policy, you know our views on that. But without a doubt, it's hard to control or to discipline the market when you're up against all the different emanations of the product arriving essentially illegally into the marketplace, which obviously also benefits from less disciplined trade channels, so completely invisible trade channels, if you like, and so on. As for your questions about synthetic versus dry, so just to frame it, the way we look at the data in the U.S., for instance, there are all-new things coming into the market. There's a fairly long list of different SKUs and the moist or others. And this whole market, the dry portion of the market, if I'm not mistaken, moved year on year by barely 20 basis points. Looking at the big picture, there are probably many shifts happening week to week, yet it appears none of them are gaining significant momentum, and so on. From the perspectives we gain through conversations with consumers, we observe — and clearly, when you go through consumer feedback, it isn't strict mathematical precision or an exact figure. Still, my view is that products that are moist, the moist pouch offerings, hold greater attraction for those who use moist snuff, correct, things like snus, and similar. Conversely, what the market shows us is that the dry version draws more interest from cigarette smokers along with those using vapor or vapes. That's everything I'm able to share with you at this point.
Faham Baig
analystThanks, everyone. I truly appreciate it. Thanks.
Jacek Olczak
executiveThanks.
Philip Stein
executiveHi, good afternoon. Thanks very much for taking the question.
Jacek Olczak
executiveMorning, Philip.
Philip Stein
executiveOne question from me, if I may. It concerns the HTU guidance. When I consider the volumes we ended up with at the close of 2024, and I then turn to the guidance range — the 10%-12% you've laid out for 2025 — but then isolate that for 2026 and examine your guidance there of 180 million-200 million in shipment volume, I'm simply attempting to grasp what underpins your confidence in my calculation, which points to a reacceleration of growth in 2026. And I'd like to get a handle on, I guess, what makes you confident that this reacceleration will indeed materialize in 2026. Thank you.
Jacek Olczak
executiveOkay, so like I mentioned before, when it comes to the 2025 guidance, we basically kept things very low and concentrated mainly on natural expansion within the markets we already serve. Of course, once you get past 2025 and into 2026, it seems perhaps wiser or more reasonable to expect that certain regions will eventually come around and make their markets available for the new offering. One thing we may not have communicated clearly enough in what we said and in our earlier responses is that roughly 20% of heat-not-burn volumes remain something we don't truly participate in, so we're unable to capture the complete growth opportunity there. I'm talking about Russia and Ukraine, for reasons that are clear. Yet looking purely at 2024's figures, I'd say we missed out on around 0.6, possibly even more, points of growth that we'd typically anticipate achieving if those markets faced conditions similar to elsewhere, you know, like ILUMA and so on. So, fine, let's watch how that plays out. The expansion we forecast is heavily centered on organic—meaning organic refers to the regions currently at our disposal—and I believe that's solid growth. In volume terms, it's basically the same increase we've historically seen; moreover, in a wider context, we increasingly recognize the promise of multi-category, and the combined volumes of smoke-free items really form just a single category. As we're well aware, from a margin standpoint, each of them basically generates excellent possibilities. I mean, they're all highly aligned with our current position and particularly with combustibles. The next point is, and I believe we'll dive a bit deeper, attempt to dive a bit deeper into this during our CAGNY presentations. But from the consumer's angle, it's genuinely a rather attractive economic setup since we're basically capitalizing on all those investments in user acquisition and so forth. And one category, of course, carries the weight of bringing in the user, while every other product line actually gains quite nicely from the entire arrangement. So you'll be hearing us discuss this increasingly. Naturally, we'll provide you with the details on heat-not-burn, e-vape, and ZYN, but I suspect over the coming years, the emphasis will increasingly shift toward overall smoke-free rather than merely each separate one, because this in some way mirrors user trends and consumer behavior.
Philip Stein
executiveThank you very much.
Emmanuel Babeau
executiveThank you.
James Bushnell
executiveThanks. As we wrap up today's call, I want to note that, just as Jacek said, we're going to be at the CAGNY Conference on February 19th, and we'd love for you to be there with us, whether you come in person or join virtually. Thanks once more for being with us today. Should any follow-up questions come up, please reach out to the investor relations team, and enjoy the rest of your day. Thank you.
Emmanuel Babeau
executiveThank you. Speak to you soon.
Jacek Olczak
executiveThank you.
Operator
operatorThis concludes today's conference call. Thank you for participating, and you may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Philip Morris International Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Philip Morris International Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Philip Morris International Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.